Trial Profile

A Phase II Multi-Centre Study Evaluating the Efficacy of Dacomitinib for Patients With Epidermal Growth Factor Receptor (EGFR)-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expression or Other Novel Emerging Biomarkers

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dacomitinib (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Biomarker; Therapeutic Use

11 Jun 2025 Planned End Date changed from 1 Jun 2028 to 1 May 2027.
11 Jun 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Apr 2027.
11 Jun 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com